25CN-NBOMe (2C-CN-NBOMe, NBOMe-2C-CN) is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor.[1][2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H22N2O3 |
Molar mass | 326.396 g·mol−1 |
3D model (JSmol) | |
| |
|
Legality
editUnited Kingdom
editThis substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]
See also
edit- 25I-NBOMe (NBOMe-2C-I)
- 25B-NBOMe (NBOMe-2C-B)
- 25C-NBOMe (NBOMe-2C-C)
- 2C-TFM-NBOMe (NBOMe-2C-TFM)
- 25CN-NBOH (NBOH-2C-CN)
References
edit- ^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–9. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
- ^ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
- ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.